Pumas-AI, Inc.
Dhanashri Gudi has a diverse work experience spanning over several years. Dhanashri is currently the Head of Business Development at Pumas-AI, Inc. since March 2023. Prior to that, they served as the Senior Director of Business Development and Strategy at Simulations Plus, Inc. from October 2022 to March 2023. From June 2021 to December 2022, they held the position of Director of Business Development and Strategy at Cognigen Corporation, a Simulations Plus Company.
Before joining the pharmaceutical industry, Dhanashri worked at Xybion Corporation where they served as a Product Manager and Subject Matter Expert from January 2021 to June 2021. Prior to that, they worked as a Business Analyst from July 2019 to January 2021.
Dhanashri also has entrepreneurial experience as they were the Founder of EduCater from October 2011 to March 2018.
Dhanashri'searlier experience includes serving as the Director of Grindlays Pharmaceuticals Pvt. Ltd from February 2008 to December 2015. In this role, they had various responsibilities including overseeing manufacturing and quality control. Dhanashri also collaborated with manufacturers to improve efficiency and production capacity.
Before that, Dhanashri worked as a Senior Research Scientist at Jubilant Biosys from October 2007 to January 2008. Dhanashri also worked as a Research Scientist at AbbVie from June 2005 to July 2007, where they were involved in drug discovery and development, conducting in vivo and in vitro studies.
Dhanashri started their career as a Post-Doctoral Fellow in Clinical Pharmacology at Indiana University School of Medicine from March 2003 to June 2005. During this time, they evaluated screening tools for studying enzyme induction and inhibition and designed clinical studies for drug-drug and drug-herb interactions.
Dhanashri began their journey in the field of pharmaceutical research as a Graduate student/Research Assistant at West Virginia University from 1998 to 2002.
Overall, Dhanashri Gudi has a wealth of experience in business development, strategy, pharmaceutical research, and entrepreneurship.
Dhanashri Gudi completed their education in a chronological order. Dhanashri first attended I E S English Medium School from 1980 to 1990, during which no specific degree or field of study is mentioned. Dhanashri then enrolled at Prin. KMKundnani College of Pharmacy from 1992 to 1996, where they studied Pharmaceutical Sciences and obtained a degree in B.Pharm. Sci. Following that, they attended Bombay College of Pharmacy, Mumbai University from 1996 to 1998, specializing in Pharmaceutical Chemistry and earning a degree in M.Pharm.Sci. Dhanashri's educational journey continued at West Virginia University between 1998 and 2002, where they pursued a Ph.D in Pharmaceutical Sciences. In addition to their formal education, they obtained a certification as a Certara Certified NCA Analyst from Certara in June 2020.
This person is not in any teams
This person is not in any offices
Pumas-AI, Inc.
Pumas-AI was founded by Dr. Joga Gobburu and Dr. Vijay Ivaturi, driven by a team of scientists at the University of Maryland in partnership with scientific computing experts. The solutions offered at Pumas-AI are fine-tuned to the needs of healthcare research, regulation and delivery, with a central vision to double pharmaceutical and patient caresuccess by democratizing tools and education in the healthcare data analytics space. With a focused goal on providing better solutions for patient care, be it via pharmaceutical drug development innovation or tools for point of care, Pumas-AI aims to bring value, innovation and efficiency to healthcare.Pumas is a one-stop integrated modeling and simulation platform designed to provide analytic capabilities and support high-performance drug development teams where collaboration is key. Developed for drug/biotech development and therapeutic decision making, it leverages the power of the Julia programming language to combine modern AI with traditional mechanistic models to gain massive computational efficiency. With its complete range of analytics capabilities, Pumas gives pharmaceutical/biotech companies and their investors usable quantitative metrics on technical, regulatory, and commercial success probabilities. Pumas was developed as a cloud-first technology that allows scientists scale to thousands of CPUs and GPUs with a single click. The software is free for non-commercial research and training.